Lupin gets 6 observations from USFDA for Pithampur plant
The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024.
)
Drug firm Lupin on Saturday said the US health regulator has issued six observations after inspecting its Madhya Pradesh-based manufacturing facility.
The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024, Lupin said in a regulatory filing.
The inspection closed with three observations each on the API and finished product side, it added.
"We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe," the Mumbai-based drug maker said.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
04:17 PM IST
Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market
Sunsure Energy to supply 21 MW solar power to Lupin